← Back to Clinical Trials
Recruiting NCT06278558

NCT06278558 Psychological Factors Influencing Cancer Post-traumatic Growth

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06278558
Status Recruiting
Phase
Sponsor Centre Hospitalier de Valenciennes
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 289 participants
Start Date 2023-11-10
Primary Completion 2026-11-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Interviews with a psychologist/psychiatrist

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 289 participants in total. It began in 2023-11-10 with a primary completion date of 2026-11-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study focuses on post-traumatic growth (positive changes linked to appreciation of life, personal strengths, social relationships...) in the context of different types of cancer and with a longitudinal approach to the care pathway. The aim of the study is to better understand whether psychological variables (emotional competence, psychological flexibility, psychological distress) and patients' care satisfaction, assessed at the start of the cancer treatment pathway, can influence their post-traumatic growth at the end of the chemotherapy protocol and 6 months later.

Eligibility Criteria

Inclusion Criteria: * Patients over 18 years of age * Patients in the initial phase of curative treatment for a 1st solid cancer * At the start of neo-adjuvant or adjuvant chemotherapy (1st course or 2nd course) * At less than 6 months from the initial diagnosis * Patient having given written consent to participate in the study Exclusion Criteria: * Patients with a previous history of cancer * Patients with incurable cancer progression, recurrence or relapse * Metastatic, brain, hematological or skin cancer * Patients who have difficulty understanding written French * Patient psychologically or physically unable to answer questionnaires

Contact & Investigator

Central Contact

Anne-Sophie Baudry

✉ baudry-as@ch-valenciennes.fr

📞 0327140523

Principal Investigator

Anne-Sophie Baudry

PRINCIPAL INVESTIGATOR

CH de Valenciennes

Frequently Asked Questions

Who can join the NCT06278558 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06278558 currently recruiting?

Yes, NCT06278558 is actively recruiting participants. Contact the research team at baudry-as@ch-valenciennes.fr for enrollment information.

Where is the NCT06278558 trial being conducted?

This trial is being conducted at Valenciennes, France.

Who is sponsoring the NCT06278558 clinical trial?

NCT06278558 is sponsored by Centre Hospitalier de Valenciennes. The principal investigator is Anne-Sophie Baudry at CH de Valenciennes. The trial plans to enroll 289 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology